Early health technology assessment is increasingly being used to support health economic evidence development during early stages of clinical research. Such early models can be used to inform research and development about the design and management of new medical technologies to mitigate the risks, perceived by industry and the public sector, associated with market access and reimbursement. Ove...

BACKGROUND Reimbursement decisions are conventionally based on evidence from randomised controlled trials (RCTs), which often have high internal validity but low external validity. Real-world data (RWD) may provide complimentary evidence for relative effectiveness assessments (REAs) and cost-effectiveness assessments (CEAs). This study examines whether RWD is incorporated in health technology a...

International measures to address environmental problems increasingly rely on scientific information, and a growing number of international agreements require periodic scientific re-assessments. However, the arena of scientific assessment, governed by a combination of scientific criteria and political interests, is not well-understood, and few case studies have mapped the influence of scientifi...